Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 10/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8989641 | 0.95 | KCNQ2 (0.42) | DRD4CCKBRKCNQ2RIPK1JAK2 | |
| SCHEMBL8990120 | 0.87 | DRD4 (0.46) | DRD4CCKBRKCNQ2SLC6A2SLC6A4 | |
| SCHEMBL12259821 | 0.86 | CCKBR (0.39) | DRD4CCKBRKCNQ2RIPK1JAK2 | |
| SCHEMBL8990016 | 0.85 | DRD4 (0.44) | DRD4CCKBRKCNQ2SLC6A2SLC6A4 | |
| SCHEMBL8990046 | 0.84 | RAB9A (0.41) | CCKBRNPC1EPHX2HTT | |
| SCHEMBL8989610 | 0.84 | HTT (0.40) | CCKBRNTRK1NPC1EPHX2HTT | |
| SCHEMBL2389167 | 0.84 | CCKBR (0.39) | CCKBRNPC1HTT | |
| SCHEMBL8990113 | 0.84 | DRD4 (0.43) | DRD4KCNQ2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8989647 | 0.83 | EPHX2 (0.43) | CCKBREPHX2HTT | |
| SCHEMBL9054838 | 0.82 | KCNQ2 (0.36) | DRD4CCKBRKCNQ2RIPK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431702-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8309729-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188279-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | DRD4 2347/4885CCKBR 1764/4885KCNQ2 54/4885 |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | DRD4 2347/4885CCKBR 1764/4885KCNQ2 54/4885 |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | DRD4 2347/4885CCKBR 1764/4885KCNQ2 54/4885 |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | DRD4 2347/4885CCKBR 1764/4885KCNQ2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.